Eloxx Pharmaceuticals, Inc.

OTCPK:ELOX Stock Report

Market Cap: US$3.3m

Eloxx Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Eloxx Pharmaceuticals ha incrementado sus ingresos a un ritmo medio anual de 7.1%, mientras que la industria Pharmaceuticals vio crecer sus ingresos growing a 8.5% anualmente.

Key information

7.1%

Earnings growth rate

29.0%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Sep 14

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Aug 15

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

Sep 09
Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

Eloxx Pharmaceuticals EPS misses by $0.06

May 06

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

Feb 17
What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

Revenue & Expenses Breakdown
Beta

How Eloxx Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ELOX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-201010
30 Jun 230-24913
31 Mar 230-311019
31 Dec 220-361123
30 Sep 220-421327
30 Jun 220-441528
31 Mar 220-701926
31 Dec 210-672122
30 Sep 210-611917
30 Jun 210-571815
31 Mar 210-291513
31 Dec 200-351514
30 Sep 200-401818
30 Jun 200-462121
31 Mar 200-532425
31 Dec 190-512426
30 Sep 190-532627
30 Jun 190-522625
31 Mar 190-512922
31 Dec 180-472620
30 Sep 180-452022
30 Jun 180-381520
31 Mar 180-29618
31 Dec 170-24316
30 Sep 170-16211
31 Dec 160-1119
31 Dec 150-716

Beneficios de calidad: ELOX actualmente no es rentable.

Creciente margen de beneficios: ELOX actualmente no es rentable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Tendencia de beneficios: ELOX no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 7.1% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ELOX en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ELOX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-17.3%).


Return on Equity

Alto ROE: ELOXEl pasivo de la empresa supera su activo, por lo que es difícil calcular su Rentabilidad de los fondos propios.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.